Literature DB >> 32570843

The Quality of Practice Guidelines for Melanoma: A Methodologic Appraisal with the AGREE II and AGREE-REX Instruments.

Theresa Steeb1,2, Anja Wessely1,2, Konstantin Drexler3, Martin Salzmann4, Frédéric Toussaint1,2, Lucie Heinzerling1,2, Markus Reinholz5, Carola Berking1,2, Markus V Heppt1,2.   

Abstract

Multiple guidelines on cutaneous melanoma (CM) are available from several consortia and countries. To provide up-to-date guidance in the rapidly changing field of melanoma treatment, guideline developers have to provide regular updates without compromises of quality. We performed a systematic search in guideline databases, Medline and Embase to identify guidelines on CM. The methodological quality of the identified guidelines was independently assessed by five reviewers using the instruments "Appraisal of Guidelines for Research and Evaluation" (AGREE II) and "Recommendation EXcellence" (AGREE-REX). We performed descriptive analysis, explored subgroup differences using the Kruskal-Wallis (H) test and examined the relationship between distinct domains and items of the instruments with Spearman's correlation. Six guidelines by consortia from Australia, France, Germany, Scotland, Spain and the United States of America were included. The German guideline fulfilled 71%-98% of criteria in AGREE II and 78%-96% for AGREE-REX, obtaining the highest scores. Deficiencies in the domains of "applicability" and "values and preferences" were observed in all guidelines. The German and Spanish guidelines significantly differed from each other in most of the domains. The domains "applicability" and "values and preferences" were identified as methodological weaknesses requiring careful revision and improvement in the future.

Entities:  

Keywords:  AGREE; cutaneous melanoma; level of evidence; melanoma treatment; practice guideline

Year:  2020        PMID: 32570843     DOI: 10.3390/cancers12061613

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  5 in total

1.  DIRAS2 Is a Prognostic Biomarker and Linked With Immune Infiltrates in Melanoma.

Authors:  Wenli Xue; Hongbo Zhu; Hongye Liu; Hongxia He
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

Review 2.  The Quality and Clinical Applicability of Recommendations in Ostomy Guidelines: A Systematic Review.

Authors:  Jiamin Li; Qiuwen Zhang; Xinjuan Wu; Dong Pang
Journal:  Risk Manag Healthc Policy       Date:  2022-08-09

3.  Significance of immunogenic cell death-related genes in prognosis prediction and immune microenvironment landscape of patients with cutaneous melanoma.

Authors:  Weijiang Fu; Guangxin Ma
Journal:  Front Genet       Date:  2022-09-21       Impact factor: 4.772

4.  Evaluation of the clinical practice guidelines and consensuses on calcium and vitamin D supplementation in healthy children using the Appraisal of Guidelines for Research and Evaluation II instrument and Reporting Items for Practice Guidelines in Healthcare statement.

Authors:  Lanzhi He; Pengxiang Zhou; Xin Zhou; Shuxia Tian; Jing Han; Suodi Zhai
Journal:  Front Nutr       Date:  2022-09-27

5.  A Critical Appraisal of Evidence- and Consensus-Based Guidelines for Actinic Keratosis.

Authors:  Anja Wessely; Theresa Steeb; Franz Heppt; Annkathrin Hornung; Matthias D Kaufmann; Elias A T Koch; Frédéric Toussaint; Michael Erdmann; Carola Berking; Markus V Heppt
Journal:  Curr Oncol       Date:  2021-02-19       Impact factor: 3.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.